Singapore Markets closed

Hikma Pharmaceuticals PLC (HKMPF)

Other OTC - Other OTC Delayed Price. Currency in USD
Add to watchlist
18.190.00 (0.00%)
At close: 03:35PM EDT
Full screen
Trade prices are not sourced from all markets
Previous close18.19
Open19.03
Bid0.00 x 0
Ask0.00 x 0
Day's range18.19 - 18.19
52-week range17.78 - 37.70
Volume1
Avg. volume432
Market cap4.339B
Beta (5Y monthly)-0.07
PE ratio (TTM)9.05
EPS (TTM)2.01
Earnings dateN/A
Forward dividend & yield0.50 (2.42%)
Ex-dividend date17 Mar 2022
1y target estN/A
  • Reuters

    Drugmaker Hikma drops on slashing generics unit forecasts

    The London-listed drugmaker now expects revenue from its generics unit to be between $710 million and $750 million for 2022, with core operating margin of around 20%. The revised outlook comes in stark contrast to the company's trading statement last week, when it had forecasted revenue from the business to grow 8% to 10% over 2021 sales of $820 million and predicted core operating margin in the range of 24% to 25%. FTSE 100-listed shares of Hikma, which supplies many generic drugs including pain medications, anaesthetics and sedatives, were down 9.6% at 1,667.5 pence by 0739 GMT and were the biggest loser on the UK blue-chip index.

  • CNW Group

    Hikma confirms that it has not signed a licensing agreement with Opiant Pharmaceuticals

    Hikma Pharmaceuticals PLC (Hikma) confirms that it has not entered into any transaction with Opiant Pharmaceuticals, contrary to a PR Newswire announcement issued today indicating that Opiant Pharmaceuticals and Hikma have entered into a commercialisation and license agreement for OPNT003, Nasal Nalmefene, in Europe and the UK.